	For	m PT(	D-1449			Sheet 1 of 2					
			- · · · •		SURE CITATION	Applicant		ryphicadon 1.	Application Number 00/700,330		
1	INFO MATION DISCLOSURE CITATION IN AN APPLICATION						Malaya CHATTERJEE et al				
	JUN	(Use several sheets if necessary)					Filing Date December 13, 1996		Group Art Unit 1642		
/	<b>.</b> .		البغ				Mailing Date June 30, 2004				
	MA	MARK OF					······································				
			<del>,</del>		U.S. PA	T DOCUMENTS					
	1	miner itials	Ref. No.	Date	Document No.		Name	Class	Subclass	Filing Date If Appropriate	
		R	1.	08/14/2001	6,274,143	Cha	itterjee et al.				
	FOREIGN PATENT DOCUMENTS  Examiner Ref. Date Document No. Country Class Subclass Tra									Translation	
	Initials		No.		2004110111101		Country	Class	Subclass	YES NO	
	5h		2.	08/08/1991	WO 91/11508	WII					
		-	3.	05/29/1992	WO 92/08495	_	DUPLICATE				
	<u> </u>	4	4.	05/23/2002	WO 02/40501	WII				\ \	
			T	Τ	ОТНЕ	R DO	DCUMENTS	(includi)	ng author, title, Da	ite, Pertinent Pages, Etc.)	
	Examiner Ref. Initials No.			Title							
	S72 5.		5.	Amalfitano, A.et al. (2002). "Separating Fact From Fiction: Assessing the Potential of Modified Adenovirus Vectors for Use in Human Gene Therapy," Current Gene Therapy 2(2):111-133.							
Duplacht Duplach	6. Benvenuti, F. et al. (2000). "Anti-idiotypic DNA Vaccines for Lymphoma Imr the Presence of Both Variable Region Genes for Tumor Protection," Gene The							oma Immunot Tene Therapy	therapy Require 7(7):605-611.		
Duplic	TE		7.	Benvenuti, F. et al. (2001). "Anti-idiotypic Antibodies Induced by Genetic Immunisation are Directe Exclusively Against Combined VL/VH Determinants," Gene Therapy 8(20):1555-1561.							
	8. Berzoksky, J.A. and Berkower, I.I. (1993). "Immunogencity and Antigen Structure," (Fundamental Immunology, William E. Paul ed. Rayen Press NY, page 242							e," Chapter 8 In			
Dupicc	9. Bodey, B. et al. (2000). "Failure of Cancer Vaccines: The Significant Limitations of this Appro Immunotherapy," Anticancer Research 20:2665-2676.								this Approach to		
			Browning, J. L. et al. (1993). "Lymphotoxin β, a Novel Member of the TNF Family That Forms a Heteromeric Complex with Lymphotoxin on the Cell Surface," Cell (72):847-856.								
			11.		. et al. (1985). "Nucl					onal Antibodies,"	
	,	<b>V</b>	12.	De Waele, P. et al. (1988). "Expression in Non-Lymphoid Cells of Mouse Recombinant Immunoglobulin Directed Against The Tumour Marker Human Placental Alkaline Phosphatase," Eur. J. Biochem. 176:287-295.							
	E.	XAMIN	ER:	1			DATE CONSI	DERED:	12/15	104	
	EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.										

PTO/SB/ 08 (2-92) pa- 746601

			O-1449		Docket Number 304142000321	Application Number 08/766,350			
		DINFC	CAM	TION DISCLOSURE CITATION	Applicant				
1	′ I		- <b>2</b> / 11	N AN APPLICATION	Malaya CHATTERJEE et al				
( }	JUN	3 0,20	04 🕏	(Use several sheets if necessary)	Filing Date December 13, 1996	Group Art Unit 1642			
'	<b>\1</b>	·	35.5		Mailing Date June 30, 2004				
	24	DEMAR							
DUPLI	12 ATE SP 13.			Gavilondo, J.V. et al. (2000). "Antibody Engineering at the Millennium," <i>Biotechiques</i> 29(1): 128-145.					
	_		14.	Journal of Biotechnology 34:269-28/.					
Pupiz			15.	145(7):2312-2321.	losely Related Antibodies Dominates The Primary Antibody of The A/PR/8/34 Influenza Virus Hemagglutinin," J. Immun.				
	CATE		16.	Kennedy, R. C. et al. (1985). "Vaccines Utilizing Internal Image Anti-Idiotypic Antibodies that Mimic Antigens of Infectious Organisms," Biotechniques 3(5):404-410.					
			17.	Liu, A. Y. et al. (1987). "Production of a Mouse-Human Chimeric Monoclonal Antibody to CI With Potent Fc-Dependent Biologic Activity," J. Immunol. 139(10):3521-3526.					
		<u> </u>	18.	with specificity For a Defined Epitope	n Gene Selection of Immunoglobulin G-Expressing B Cells On Type II Collagen," Eur. J. Immunol. 23:2503-2510.				
			19.	Pandha, H. S et al. (2000). "Oncologia Investigation Drugs 1(1):122-134.	al Applications of Gene Therapy," Current Opinion in				
			20.	Pandya, K. J. et al. (1985). "A Retrosp Eastern Cooperative Oncology Group Preliminary Report," <i>Cancer</i> 55(1):202	ctive Study of Earliest Indicators of Recurrence in Patients On djuvant Chemotherapy Trials For Breast Cancer. A 205.				
Duplic			21.	Patterson, A. P. (2003). "Principles Inv Retroviral Vectors. Notification of a Se Service, pp.1-3.	vestigators for Human Gene Transfer Trials Employing erious Adverse Event. <u>Department of Health and Human</u>				
	ATE		22.	Reeck et al. (1987). "Homology," Prot of It," Cell 50(5):667.	otein and Nucleic Acids: A Terminology Muddle and Way out				
			23.	Schouten, D. et al. (1993). "Developme High Density Lipoproteins," Molecular	nent of Lipoprotein-like Lipid Particles for Drug Targeting Neo- ter Pharmacology 44(2):486-492.				
		L	24.		nunoglobulin Gene is Formed by Site-Specific Recombination ature 280(5721):370-375.				
			25.	Shlomchik, M. et al. (1990). "Anti-DNA Expansion and Somatic Mutation," J. E					
			26.	Stevenson, F. K. et al. (1995). "Idiotypi Reviews 145:211-228.	ic DNA Vaccines Against B-Cell Lymphoma," Immunological				
PhPLI	CAIC		27.	Zeytin, H. E. et al. (2000). "Construction Single-Chain Variable Fragment of the Associated Antigen Disialoganglioside	Anti-Idiotyne Antihody 1 A 7 M	micking the Turnor			
	▶         28.         Ve			Verma, I. M. et al. (1997). "Gene Therapy-Promises, Problems and Prospects," Nature 389:239-242.					
	E	XAMIN	JER:	1~	DATE CONSIDERED: 12/15-104				
	EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.								
		B/ 08 (2							